Genetic and phenotypic characteristics of staphylococcus aureus isolates from cystic fibrosis patients in Austria

Respiration

Volumn 89, Issue 5, 2015, Pages 390-395

  Masoud Landgraf, Lilian ^a   Johler, Sophia ^b   Badura, Alexandra ^a   Feierl, Gebhard ^a   Luxner, Josefa ^a   Wagner Eibel, Ute ^a   Eber, Ernst ^a   Zarfel, Gernot ^a   Grisold, Andrea J ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Antimicrobial resistance; Cystic fibrosis; spa typing; Staphylococcus aureus; Virulence genes

Indexed keywords

CEFOXITIN; CLINDAMYCIN; COTRIMOXAZOLE; ENTEROTOXIN; ERYTHROMYCIN; EXFOLIATIN; GENTAMICIN; HEMOLYSIN; LEUKOCIDIN; PENICILLIN DERIVATIVE; TRIMETHOPRIM; BACTERIAL DNA; BACTERIAL TOXIN;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; AUSTRIA; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CHILD; CLINICAL ARTICLE; CYSTIC FIBROSIS; DNA MICROARRAY; FEMALE; GENETIC ANALYSIS; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; BACTERIUM IDENTIFICATION; GENETICS; GENOTYPE; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOGENICITY; VIRULENCE;

BACTERIAL TOXINS; BACTERIAL TYPING TECHNIQUES; CYSTIC FIBROSIS; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROTOXINS; GENOTYPE; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; STAPHYLOCOCCUS AUREUS; VIRULENCE;

EID: 84930276188     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000377707     Document Type: Article

References (24)

1. O?Sullivan BP, Freedman SD: Cystic fibrosis. Lancet 2009; 373: 1891-1904.
2. Ratjen F, Doring G: Cystic fibrosis. Lancet 2003; 361: 681-689.
3. Saiman L: Microbiology of early CF lung disease. Paediatr Respir Rev 2004; 5(suppl A):S367-S369.
4. Champion EA, Miller MB, Popowitch EB, Hobbs MM, Saiman L, et al: Antimicrobial susceptibility and molecular typing of MRSA in cystic fibrosis. Pediatr Pulmonol 2014; 49: 230-237.
5. Goss C, Muhlebach M: Review: Staphylococcus aureus and MRSA in cystic fibrosis. J Cyst Fibros 2011; 10: 298-306.
6. Rosenthal VD, Bijie H, Maki DG, Mehta Y, Apisarnthanarak A, et al: International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009. Am J Infect Control 2012; 40: 396-407.
7. Ren CL, Morgan WJ, Konstan MW, Schechter MS, Wagener JA, et al: Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function. Pediatr Pulmonol 2007; 42: 513-518.
8. Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP: Persistent methicillinresistant Staphylococcus aureus and rate of FEV 1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008; 178: 814-821.
9. Muhlebach MS, Miller M, LaVange LM, Mayhew G, Goodrich JS, et al: Treatment intensity and characteristics of MRSA infection in CF. J Cyst Fibros 2011; 10: 201-206.
10. The European Committee on Antimicrobial Susceptibility Testing: Breakpoint tables for interpretation of MICs and zone diameters, version 2.0, 2012-01-01.
11. Ruppitsch W, Indra A, Stoger A, Mayer B, Stadlbauer S, et al: Classifying spa types in complexes improves interpretation of typing results for methicillin-resistant Staphylococcus aureus . J Clin Microbiol 2006; 44: 2442-2448.
12. Huson DH, Bryant D: Application of phylogenetic networks in evolutionary studies. Mol Biol Evol 2006; 23: 254-267.
13. Wattinger L, Stephan R, Layer F, Johler S: Comparison of Staphylococcus aureus isolates associated with food intoxication with isolates from human nasal carriers and human infections. Eur J Clin Microbiol Infect Dis 2012; 31: 455-464.
14. Campana S, Cocchi P, Doring G, Taccetti G, Moroney SM: Emergence of an epidemic clone of community-associated methicillinresistant Panton-Valentine leucocidin-negative Staphylococcus aureus in cystic fibrosis patient populations. J Clin Microbiol 2007; 45: 3146, author reply 3146-3147.
15. Taccetti G, Cocchi P, Festini F, Braggion C, Campana S: Community-associated meticillin-resistant Staphylococcus aureus . Lancet 2010; 376: 767-768.
16. Gillet-Vittori L, Afanetti M, Dupont A, Gondon E, Dupont D: Life-threatening Panton-Valentine leukocidin-associated staphylococcal infections in children. A broad spectrum of clinical presentations. Arch Pediatr 2014; 21: 1220-1225.
17. Grisold AJ, Zarfel G, Stoeger A, Feierl G, Raggam RB, et al: Emergence of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) in southeast Austria. J Infect 2009; 58: 168-170.
18. Krziwanek K, Luger C, Sammer B, Stumvoll S, Stammler M, et al: PVL-positive MRSA in Austria. Eur J Clin Microbiol Infect Dis 2007; 26: 931-935.
19. Cookson BD, Robinson DA, Monk AB, Murchan S, Deplano A, et al: Evaluation of molecular typing methods in characterizing a European collection of epidemic methicillinresistant Staphylococcus aureus strains: the HARMONY collection. J Clin Microbiol 2007; 45: 1830-1837.
20. Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A, et al: European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros 2014; 13: 23-42.
21. Luedicke C, Slickers P, Ehricht R, Monecke S: Molecular fingerprinting of Staphylococcus aureus from bone and joint infections. Eur J Clin Microbiol Infect Dis 2010; 29: 457-463.
22. Monecke S, Luedicke C, Slickers P, Ehricht R: Molecular epidemiology of Staphylococcus aureus in asymptomatic carriers. Eur J Clin Microbiol Infect Dis 2009; 28: 1159-1165.
23. Rolo J, Miragaia M, Turlej-Rogacka A, Empel J, Bouchami O, et al: High genetic diversity among community-associated Staphylococcus aureus in Europe: results from a multicenter study. PLoS One 2012; 7:e34768.
24. Hirschhausen N, Block D, Bianconi I, Bragonzi A, Birtel J, et al: Extended Staphylococcus aureus persistence in cystic fibrosis is associated with bacterial adaptation. Int J Med Microbiol 2013; 303: 685-692.